Jane Hübertz Frederiksen

Dr. Jane Hübertz Frederiksen


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2012 in Journal of Aging Research
Verified
Journal Article
Open access
PDF file
CDClaus Desler
Claus Desler
THThomas Lau Hansen
Thomas Lau Hansen
JFJane Hübertz Frederiksen
Jane Hübertz Frederiksen
MMMaiken Lise Marcker
Maiken Lise Marcker
KSKeshav K. Singh
Keshav K. Singh
LRLene Juel Rasmussen
Lene Juel Rasmussen
Oxidative phosphorylation is an indispensable resource of ATP in tissues with high requirement of energy. If the ATP demand is not met, studies suggest that this will lead to senescence and cell death in the affected tissue. The term reserve respiratory capacity or spare respiratory capacity is used to describe the amount of extra ATP that can be produced by oxidative phosphorylation in case of a sudden increase in energy demand. Depletion of the reserve respiratory capacity has been related to a range of pathologies affecting high energy requiring tissues. During aging of an organism, and as a result of mitochondrial dysfunctions, the efficiency of oxidative phosphorylation declines. Based on examples from the energy requiring tissues such as brain, heart, and skeletal muscle, we propose that the age-related decline of oxidative phosphorylation decreases the reserve respiratory capacity of the affected tissue, sensitizes the cells to surges in ATP demand, and increases the risk of resulting pathologies.

Verified
Journal Article
Open access
PDF file
JFJane Hübertz Frederiksen
Jane Hübertz Frederiksen
SJSara B. Jensen
Sara B. Jensen
Zeynep TümerZeynep Tümer
Zeynep Tümer
THThomas Hansen
Thomas Hansen
Lynch syndrome (LS) is one of the most common hereditary cancer predisposition syndromes worldwide. Individuals with LS have a high risk of developing colorectal or endometrial cancer, as well as several other cancers. LS is caused by autosomal dominant pathogenic variants in one of the DNA mismatch repair (MMR) genes MLH1, MSH2, PMS2 or MSH6, and typically include truncating variants, such as frameshift, nonsense or splicing variants. However, a significant number of missense, intronic, or silent variants, or small in-frame insertions/deletions, are detected during genetic screening of the MMR genes. The clinical effects of these variants are often more difficult to predict, and a large fraction of these variants are classified as variants of uncertain significance (VUS). It is pivotal for the clinical management of LS patients to have a clear genetic diagnosis, since patients benefit widely from screening, preventive and personal therapeutic measures. Moreover, in families where a pathogenic variant is identified, testing can be offered to family members, where non-carriers can be spared frequent surveillance, while carriers can be included in cancer surveillance programs. It is therefore important to reclassify VUSs, and, in this regard, functional assays can provide insight into the effect of a variant on the protein or mRNA level. Here, we briefly describe the disorders that are related to MMR deficiency, as well as the structure and function of MSH6. Moreover, we review the functional assays that are used to examine VUS identified in MSH6 and discuss the results obtained in relation to the ACMG/AMP PS3/BS3 criterion. We also provide a compiled list of the MSH6 variants examined by these assays. Finally, we provide a future perspective on high-throughput functional analyses with specific emphasis on the MMR genes.

8 September 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Bárbara HenriquesBárbara Henriques
Bárbara Henriques
TLTânia G. Lucas
Tânia G. Lucas
JRJoão V. Rodrigues
João V. Rodrigues
JFJane Hübertz Frederiksen
Jane Hübertz Frederiksen
MTMiguel Teixeira
Miguel Teixeira
Cláudio M. GomesCláudio M. Gomes
Cláudio M. Gomes
ETHE1 is an iron-containing protein from the metallo β-lactamase family involved in the mitochondrial sulfide oxidation pathway. Mutations in ETHE1 causing loss of function result in sulfide toxicity and in the rare fatal disease Ethylmalonic Encephalopathy (EE). Frequently mutations resulting in depletion of ETHE1 in patient cells are due to severe structural and folding defects. However, some ETHE1 mutations yield nearly normal protein levels and in these cases disease mechanism was suspected to lie in compromised catalytic activity. To address this issue and to elicit how ETHE1 dysfunction results in EE, we have investigated two such pathological mutations, ETHE1-p.Arg163Gln and p.Arg163Trp. In addition, we report a number of benchmark properties of wild type human ETHE1, including for the first time the redox properties of the mononuclear iron centre. We show that loss of function in these variants results from a combination of decreased protein stability and activity. Although structural assessment revealed that the protein fold is not perturbed by mutations, both variants have decreased thermal stabilities and higher proteolytic susceptibilities. ETHE1 wild type and variants bind 1±0.2 mol iron/protein and no zinc; however, the variants exhibited only ≈10% of wild-type catalytically activity. Analysis of the redox properties of ETHE1 mononuclear iron centre revealed that the variants have lowered reduction potentials with respect to that of the wild type. This illustrates how point mutation-induced loss of function may arise via very discrete subtle conformational effects on the protein fold and active site chemistry, without extensive disruption of the protein structure or protein-cofactor association.

1 November 2015 in Mitochondrion
Verified
Journal Article
Open access
CDClaus Desler
Claus Desler
JFJane Hübertz Frederiksen
Jane Hübertz Frederiksen
MAMaria Angleys
Maria Angleys
SMScott Maynard
Scott Maynard
GKGuido Keijzers
Guido Keijzers
LRLene Juel Rasmussen
Lene Juel Rasmussen
Mitochondrial bioenergetics, mitochondrial reactive oxygen species (ROS) and cellular levels of nucleotides have been hypothesized as early indicators of Alzheimer's disease (AD). Utilizing relative decline of cognitive ability as a predictor of AD risk, we evaluated the correlation between change of cognitive ability and mitochondrial bioenergetics, ROS and cellular levels of deoxyribonucleotides. Change of cognitive abilities, scored at ages of approximately 20 and 57 was determined for a cohort of 1985 male participants. Mitochondrial bioenergetics, mitochondrial ROS and whole-cell levels of deoxyribonucleotide triphosphates were measured in peripheral blood mononuclear cells (PBMCs) from a total of 103 selected participants displaying the most pronounced relative cognitive decline and relative cognitive improvement. We show that relative cognitive decline is associated with higher PBMC content of deoxythymidine-triphosphate (dTTP) (20%), but not mitochondrial bioenergetics parameters measured in this study or mitochondrial ROS. Levels of dTTP in PBMCs are indicators of relative cognitive change suggesting a role of deoxyribonucleotides in the etiology of AD.

10 January 2012 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Closed access
PDF file
Peter BrossPeter Bross
Peter Bross
JFJane Hübertz Frederiksen
Jane Hübertz Frederiksen
ABAnne S. Bie
Anne S. Bie
JHJakob Hansen
Jakob Hansen
JPJohan Palmfeldt
Johan Palmfeldt
ECErnst Christensen
Ernst Christensen

15 August 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
USUlrik Kristoffer Stoltze
Ulrik Kristoffer Stoltze
THThomas Hansen
Thomas Hansen
JFJon Foss-Skiftesvik
Jon Foss-Skiftesvik
ABAnna Byrjalsen
Anna Byrjalsen
KHKasper Amund Henriksen
Kasper Amund Henriksen
KSKjeld Schmiegelow
Kjeld Schmiegelow
Purpose: Cancer predisposition syndromes (CPS) with pediatric onset are the leading known cause of childhood malignancies and are increasingly guiding clinical strategies in pediatric oncology. CPS are placed under evolutionary negative selective pressure, but pediatric pancancer studies have so far failed to investigate genomic evolutionary metrics as a guide to predict penetrance and reveal novel CPS. Experimental Design: Germline whole-genome sequencing was performed in a 5-year prospective, registry-validated, nationwide cohort of individuals diagnosed with cancer before age 18. Evolution-guided burden analysis of private germline variants in constrained genes was compared with 125,748 gnomAD exomes. Results: Across a total of 1,127 participants, 16% carried a pathogenic variant in at least one CPS gene. After genotype–phenotype matching, 9% of children in the prospective cohort (n = 651) carried a variant considered causative, a rate deemed significantly higher than in previous studies [RR, 1.54, 95% confidence interval (CI), 1.37–1.75, P = 1 × 10−14]. As predicted for a disease subject to negative Darwinian selective pressure, compared with reference adults, we found a significant excess of loss-of-function (LoF) variants in the 1,500 most constrained genes (RR, 1.54, 99% CI, 1.21–1.95, P = 4 × 10−6). Surprisingly, this excess was greater than expected, leaving a significant residual enrichment of predicted LoF variants in genes evolutionarily considered the least tolerant to damage (RR, 1.41, 99% CI, 1.09–1.80, P = 4 × 10−4). Conclusions: The high frequency of LoF variants, including in known CPS, emphasizes the need for systematic and extensive germline genomic mapping as part of the diagnostic workup of patients with childhood cancer and the linkage of such data to disease and response phenotypes to guide future pediatric oncological care and ultimately pave the way for prediagnostic interventional measures.